REG - Redx Pharma plc - Redx to Participate at Piper Sandler Conference

Redx PharmaAnnouncement

30/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211130:nRSd9275Ta&default-theme=true

RNS Number : 9275T  Redx Pharma plc  30 November 2021

REDX PHARMA PLC

("Redx" or the "Company")

 

Redx to Participate at the Piper Sandler 33rd Annual Virtual Healthcare
Conference

 

Alderley Park, UK, 30 November 2021 - Redx Pharma (AIM: REDX), the
clinical-stage biotechnology company focused on discovering and developing
novel, small molecule, highly targeted therapeutics for the treatment of
cancer and fibrotic disease, announces that Lisa Anson, Chief Executive
Officer, and Peter Collum, Chief Financial Officer, will be participating at
the Piper Sandler 33rd Annual Virtual Healthcare Conference, 30 November to 2
December.

 

A pre-recorded presentation by Lisa Anson can be accessed via the following
link: https://bit.ly/3CSvvSV (https://bit.ly/3CSvvSV)

 

 

 For further information, please contact:

 Redx Pharma Plc                                 T: +44 (0)1625 469 918

 UK Headquarters

 Lisa Anson, Chief Executive Officer
 Karl Hård, Head of Investor Relations

 k.hard@redxpharma.com

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)     T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                  T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)      T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                  T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic disease, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase
2 programme in November 2021. The Company's selective ROCK2 inhibitor product
candidate, RXC007, is in development for idiopathic pulmonary fibrosis and
commenced a Phase 1 clinical trial in June 2021. Initial results were reported
in October 2021, with full Phase 1 results expected in 2022.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by the two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by the four
strategic transactions from which has emerged the most advanced product
candidate pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3
clinical development by Eli Lilly following its acquisition of Loxo Oncology.
In addition, Redx has forged pre-clinical collaborations with AstraZeneca and
Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDKCBBPBDDDDB